Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients

Abstract Background Anti-CGRP monoclonal antibodies have shown notable effectiveness and tolerability in migraine patients; however, data on their use in elderly patients is still lacking, as clinical trials have implicit age restrictions and real-world evidence is scarce. In this study, we aimed to...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Albert Muñoz-Vendrell, Sergio Campoy, Edoardo Caronna, Alicia Alpuente, Marta Torres-Ferrus, Candela Nieves Castellanos, Marina Olivier, Jaume Campdelacreu, Joan Prat, Javier Camiña Muñiz, Francisco José Molina Martínez, Ane Mínguez-Olaondo, Marta Ruibal Salgado, Sonia Santos Lasaosa, María Pilar Navarro Pérez, Noemí Morollón, Alba López Bravo, Luis Miguel Cano Sánchez, Sonia María García-Sánchez, Jésica García-Ull, Laura Rubio-Flores, Alicia Gonzalez-Martinez, Sonia Quintas, Ana Echavarría Íñiguez, Sendoa Gil Luque, María Victoria Castro-Sánchez, Vanesa Adell Ortega, Jessica García Alhama, Nuria Berrocal-Izquierdo, Robert Belvís, Samuel Díaz-Insa, Patricia Pozo-Rosich, Mariano Huerta-Villanueva
Format:	Artigo
Sprog:	Inglês
Udgivet:	BMC 2023-06-01
Serier:	The Journal of Headache and Pain
Fag:	Calcitonin gene-related peptide Monoclonal antibodies Migraine 65 years old Real-world
Online adgang:	https://doi.org/10.1186/s10194-023-01585-2
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!